Valuation Highnoon Laboratories Limited

Stocks

End-of-day quote Pakistan S.E. Other stock markets 10/07/2026			5-day change	1st Jan Change
1,020.54 ^PKR	+1.72%		-3.24%	-0.19%

05-18	Highnoon Laboratories Appoints Dr. Shahzad Khan as Managing Director of Highnoon Life Sciences	CI
04-30	Highnoon Laboratories Limited Approves Final Cash Dividend for the Year Ended December 31, 2025	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	48,650	54,175	54,072	-	-
Change	-	11.36%	-0.19%	-	-
Enterprise Value (EV)	48,650	54,175	54,072	54,072	54,072
Change	-	11.36%	-0.19%	0%	0%
P/E	14.4x	-	-	-	-
PBR	-	-	-	-	-
PEG	-	-	-	-	-
Capitalization / Revenue	-	1.96x	1.78x	1.58x	1.41x
EV / Revenue	-	0x	1.78x	1.58x	1.41x
EV / EBITDA	-	-	-	-	-
EV / EBIT	-	-	-	-	-
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Dividend per Share ²	-	50	45	52	60
Rate of return	-	4.89%	4.41%	5.1%	5.88%
EPS ²	63.95	-	-	-	-
Distribution rate	-	-	-	-	-
Net sales ¹	-	27,706	30,398	34,163	38,399
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Net income	3,389	-	-	-	-
Net Debt	-	-	-	-	-
Reference price ²	918.22	1,022.49	1,020.54	1,020.54	1,020.54
Nbr of stocks (in thousands)	52,983	52,983	52,983	-	-
Announcement Date	26/03/25	07/04/26	-	-	-

¹PKR in Million²PKR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
HIGHNOON LABORATORIES LIMITED	-	-	-	4.41%	195M
ELI LILLY AND COMPANY	34.92x	12.63x	25.81x	0.57%	1,060B
JOHNSON & JOHNSON	27.42x	6.3x	17.1x	2.08%	619B
ABBVIE INC.	30x	7.34x	15.02x	2.76%	438B
ROCHE HOLDING AG	17.98x	4.45x	11.01x	2.97%	333B
NOVARTIS AG	21.52x	5.52x	13.36x	2.86%	282B
ASTRAZENECA PLC	21.56x	4.53x	12.65x	1.94%	267B
NOVO NORDISK A/S	14.17x	5.3x	10.9x	3.52%	218B
AMGEN INC.	23.77x	6.31x	11.12x	2.78%	196B
GILEAD SCIENCES, INC.	-46.02x	5.6x	31.12x	2.5%	161B
Average	16.15x	6.44x	16.46x	2.64%	357.41B
Weighted average by Cap.	23.86x	7.85x	18.16x	2%